Action Aptose Biosciences - APS

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

2,10

( -5,83% )

Prix Achat

2,03

Prix Vente

2,18

Volume échangé

5 785

1,98 Fourchette du Jour 2,35

0,155 Plage de 52 semaines 5,80

Clôture Veille

2,23

Ouverture

2,32

Dernière Transaction

100

2.02

Dernière heure de transaction

16:41:28

Volume moyen (3 m)

7 449

Volume financier

VWAP

Aptose Upgraded to Trade on OTCQB Market

SAN DIEGO and TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”...

Aptose Announces Deferral of Interest Payment

SAN DIEGO and TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company...

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company...

Aptose Provides Corporate Updates

Announces short-term cash advance SAN DIEGO and TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Aptose...

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple...

Aptose Announces Results from Annual and Special Meeting of Shareholders

SAN DIEGO and TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company...

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with...

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy...

Aptose Reports First Quarter 2025 Results

SAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”...

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.99	89.1891891892	1.11	2.35	1.11	13177	1.87857401	CS
4	-0.35	-14.2857142857	2.45	2.57	1.02	13870	1.57000577	CS
12	-0.7	-25	2.8	3.79	1.02	7449	1.94473753	CS
26	1.765	526.865671642	0.335	5.8	0.155	21844	0.74421238	CS
52	1.1	110	1	5.8	0.155	21235	0.57886473	CS
156	-14.4	-87.2727272727	16.5	17.4	0.155	14646	5.35693703	CS
260	-126.9	-98.3720930233	129	141	0.155	26787	45.25871008	CS

APS - Frequently Asked Questions (FAQ)

What is the current Aptose Biosciences share price?

The current share price of Aptose Biosciences is $ 2,10

What is the 1 year trading range for Aptose Biosciences share price?

Aptose Biosciences has traded in the range of $ 0,155 to $ 5,80 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
FLNTFlint Corporation	$ 0,025 (25,00%)	1 000
EGLXEnthusiast Gaming Holdings Inc	$ 0,075 (25,00%)	539,67k
TLRYTilray Brands Inc	$ 0,91 (15,19%)	1,66M
EDREndeavour Silver Corp	$ 7,41 (11,93%)	1,06M
BLDPBallard Power Systems Inc	$ 2,59 (11,64%)	550,78k
GMTNGold Mountain Mining Corp	$ 0,005 (-50,00%)	25,55k
BCTBriaCell Therapeutics Corp	$ 3,00 (-25,00%)	40,3k
FTFortune Minerals Limited	$ 0,09 (-18,18%)	704,23k
SAUSt Augustine Gold and Copper Limited	$ 0,285 (-12,31%)	580,81k
GVCGlacier Media Inc	$ 0,15 (-11,76%)	51k
IVNIvanhoe Mines Ltd	$ 11,09 (4,72%)	6,93M
TLRYTilray Brands Inc	$ 0,91 (15,19%)	1,66M
WCPWhitecap Resources Inc	$ 9,41 (-0,63%)	1,66M
NDMNorthern Dynasty Minerals Ltd	$ 2,61 (6,10%)	1,3M
WEEDCanopy Growth Corporation	$ 1,72 (1,78%)	1,14M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Aptose Biosciences Inc (APS)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés